Skip to main content

Amarin Corporation plc

corporate_fare Company Profile

Amarin Corporation plc

AMRN·NASDAQ·Life Sciences·CIK 0000897448

Amarin Corporation plc is a pharmaceutical company that develops and sells treatments to improve heart health and reduce cardiovascular risk. The company's main product is VASCEPA (icosapent ethyl). VASCEPA was initially approved by the U.S. Food and Drug Administration (FDA) in July 2012. This initial approval was for use alongside diet to lower triglyceride levels in adult patients with severe hypertriglyceridemia, defined as levels of 500 mg/dL or higher (known as the MARINE indication). On December 13, 2019, the U.S. FDA expanded VASCEPA's approved uses based on findings from the REDUCE-IT trial. VASCEPA is now also approved by the U.S. FDA for use with maximally tolerated statin therapy to reduce ongoing cardiovascular risk in specific high-risk patients (known as the REDUCE-IT indication). Amarin Corporation plc is incorporated under the laws of England and Wales. Its principal office is in Dublin, Ireland, and its registered office is in London, England. The company's primary office in the United States is located in Bridgewater, NJ.

Amarin Corporation plc (NASDAQ:AMRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for AMRN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AMRN spans 10-Q, 8-K, SCHEDULE 13D/A, DEF 14A.

Recent high-impact activity:

  • Amarin 10-Q Details First Quarterly Profit in Over Two Years and $323.4M Cash Pile
  • Amarin Posts First Profitable Quarter in Over Two Years; Cash Rises to $323.4M
  • Amarin Posts First Profit in Over Two Years as Expenses Fall 44%
  • Sarissa Capital Sells 25.7M Amarin Shares, Cutting Stake to 6.09%
  • Amarin Q2 Revenue Drops 42% to $42.2M as Licensing Income Evaporates; Cash Runway Remains Strong at $314.6M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$213.65M
Net Income
-$38.8M
Diluted EPS
-$0.09
Op. Cash Flow
$6.73M
Gross Profit
$120.87M
Operating Income
-$50.17M
Cash & Equivalents
$134.66M
Debt / Equity
0.00×
Net Margin
-18.2%
Shares Outstanding
416.21M sh
Source: 10-K · filed 2026-03-02 · accession 0001193125-26-085818

Short Interest & Short Volume

7.58 days to cover

FINRA reported short interest of 537,876 shares in AMRN as of the October 30, 2026 settlement, a 1.0% increase from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 44.5% of AMRN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)537,876 shares as of October 30, 2026
Change vs prior period▲ 1.0%
Days to cover7.58 at avg daily volume of 70,981
Daily short volume (FINRA facilities)44.5% of 102,813 shares on November 20, 2026
5-day average short volume45.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$10.57
52-week range · as of 2026-10-28 $10.57 – $20.57
Market cap
$222.83M
Volume
177.9K (2.1× avg)
3-mo avg 83.8K
Live data · 2026-11-22 05:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AMRN - Latest Insights

AMRN
Oct 28, 2026, 7:05 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.95
Real-time Price: $10.57 info
Change: -$1.38 (-12%) info
Market Cap: $222.833M info
AMRN
Oct 28, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.95
Real-time Price: $10.57 info
Change: -$1.38 (-12%) info
Market Cap: $222.833M info
AMRN
Oct 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.95
Real-time Price: $10.57 info
Change: -$1.38 (-12%) info
Market Cap: $222.833M info
AMRN
Aug 27, 2026, 6:56 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $14.07
Real-time Price: $10.57 info
Change: -$3.50 (-25%) info
Market Cap: $222.833M info
AMRN
Jul 29, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.57 info
Change: -$3.59 (-25%) info
Market Cap: $222.833M info
AMRN
Jul 29, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $10.57 info
Change: -$3.59 (-25%) info
Market Cap: $222.833M info
AMRN
Jun 30, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $15.94
Real-time Price: $10.57 info
Change: -$5.37 (-34%) info
Market Cap: $222.833M info
AMRN
Jun 04, 2026, 10:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $14.50
Real-time Price: $10.57 info
Change: -$3.93 (-27%) info
Market Cap: $222.833M info
AMRN
May 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $15.80
Real-time Price: $10.57 info
Change: -$5.23 (-33%) info
Market Cap: $222.833M info
AMRN
May 14, 2026, 9:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.78
Real-time Price: $10.57 info
Change: -$4.21 (-28%) info
Market Cap: $222.833M info
AMRN
Apr 29, 2026, 5:38 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $14.29
Real-time Price: $10.57 info
Change: -$3.72 (-26%) info
Market Cap: $222.833M info
AMRN
Apr 29, 2026, 7:13 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.96
Real-time Price: $10.57 info
Change: -$3.39 (-24%) info
Market Cap: $222.833M info
AMRN
Apr 29, 2026, 7:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $13.96
Real-time Price: $10.57 info
Change: -$3.39 (-24%) info
Market Cap: $222.833M info
AMRN
Apr 29, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.96
Real-time Price: $10.57 info
Change: -$3.39 (-24%) info
Market Cap: $222.833M info
AMRN
Apr 10, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $14.48
Real-time Price: $10.57 info
Change: -$3.91 (-27%) info
Market Cap: $222.833M info
AMRN
Apr 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.40
Real-time Price: $10.57 info
Change: -$3.83 (-27%) info
Market Cap: $222.833M info
AMRN
Mar 30, 2026, 5:57 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $10.57 info
Change: -$3.38 (-24%) info
Market Cap: $222.833M info
AMRN
Mar 02, 2026, 5:31 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $13.93
Real-time Price: $10.57 info
Change: -$3.36 (-24%) info
Market Cap: $222.833M info
AMRN
Feb 25, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.52
Real-time Price: $10.57 info
Change: -$4.95 (-32%) info
Market Cap: $222.833M info
AMRN
Jan 08, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.75
Real-time Price: $10.57 info
Change: -$3.18 (-23%) info
Market Cap: $222.833M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets